---
schema_version: "secwatch.filing_event.v1"
accession: "0001655759-24-000002"
form_type: "8-K"
ticker: "ARVN"
cik: "0001655759"
company_name: "ARVINAS, INC."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:22:09.996877+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Arvinas gets FDA/EMA clearance for ARV-393 and ARV-102; Phase 1 trials planned H1 2024

## Summary
- FDA authorized IND for ARV-393, a PROTAC BCL6 degrader.
- EMA authorized CTA for ARV-102, a PROTAC LRRK2 degrader.
- Both first-in-human Phase 1 trials expected to start in H1 2024.
- ARV-393 targets BCL6 protein; ARV-102 targets LRRK2 protein.

## SEC filing metadata
- accession: 0001655759-24-000002
- form_type: 8-K
- ticker: ARVN
- cik: 0001655759
- company_name: ARVINAS, INC.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1655759/000165575924000002/0001655759-24-000002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1655759/000165575924000002/arvn-20240107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001655759-24-000002
- JSON: https://secwatch.observer/filing/0001655759-24-000002.json
- Plain text: https://secwatch.observer/filing/0001655759-24-000002.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.